Immunotherapy formula for inducing carcinogenic autoantibodies from the international leukocyte union-2 to receptors

摘要

1. Refers to a therapeutic formula capable of producing an immune response to interleucine (IL-2), including: (a) interleucine 2 (IL-2) or any derivative produced from this docking with gene delivery or chemical binding proteins and appropriate adhesives; (b) monoclonal anti-IL-2 antibodies; (c) Vaccines based on specific tumor or growth factor antigens; (d) monoclonal antibodies against CD25. The design includes (a) plus (c) simultaneous management or sequential management.(a) Add D,(b) Items (c) and (b) plus (d). The transporter protein is P64k produced by nisera meningitis, and adyuvante is selected from alumina. IL-2-based treatment combination and other vaccines based on specific tumor antigens or tumor growth factors and chemotherapy drugs are effective means to treat cancer.